We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BsUFA II Proposes Enhanced Review Process, Restructured Fees
BsUFA II Proposes Enhanced Review Process, Restructured Fees
The FDA expects to refine the review process and fee structure for biosimilar products in the next iteration of the Biosimilar User Fee Act to improve efficiency and resource availability.